ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007

被引:630
作者
Richards, C. Sue [1 ]
Bale, Sherri [2 ]
Bellissimo, Daniel B. [3 ]
Das, Soma [4 ]
Grody, Wayne W. [5 ]
Hegde, Madhuri R. [6 ]
Lyon, Elaine [7 ]
Ward, Brian E. [8 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR USA
[2] GeneDX Inc, Gaithersburg, MD USA
[3] Mol Diagnost Blood Ctr Wisconsin, Milwaukee, WI USA
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Univ Calif Los Angeles, Sch Med, Dept Mol Genet Mol Pathol, Los Angeles, CA USA
[6] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA
[7] Univ Utah ARUP, Dept Pathol, Salt Lake City, UT USA
[8] Genom Hlth Inc, Redwood City, CA USA
关键词
clinical genetic testing; ACMG practice guideline; sequence variations; interpretation and reporting;
D O I
10.1097/GIM.0b013e31816b5cae
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
ACMG previously developed recommendations for standards for interpretation of sequence variations. We now present the updated revised recommendations. Here, we describe six interpretative categories of sequence variations: (1) sequence variation is previously reported and is a recognized cause of the disorder; (2) sequence variation is previously unreported and is of the type which is expected to cause the disorder; (3) sequence variation is previously unreported and is of the type which may or may not be causative of the disorder; (4) sequence variation is previously unreported and is probably not causative of disease; (5) sequence variation is previously reported and is a recognized neutral variant; and (6) sequence variation is previously not known or expected to be causative of disease, but is found to be associated with a clinical presentation. We emphasize the importance of appropriate reporting of sequence variations using standardized terminology and established databases, and of clearly reporting the limitations of sequence-based testing. We discuss follow-up studies that may be used to ascertain the clinical significance of sequence variations, including the use of additional tools (such as predictive software programs) that may be useful in variant classification. As more information becomes available allowing the interpretation of a new sequence variant, it is recommended that the laboratory amend previous reports and provide updated results to the physician. The ACMG strongly recommends that the clinical and technical validation of sequence variation detection be performed in a CLIA-approved laboratory and interpreted by a board-certified clinical molecular geneticist or equivalent.
引用
收藏
页码:294 / 300
页数:7
相关论文
共 13 条
[1]  
*AM COLL MED GEN, 2007, GUID CLIN GEN LAB
[2]   ConSeq: the identification of functionally and structurally important residues in protein sequences [J].
Berezin, C ;
Glaser, F ;
Rosenberg, J ;
Paz, I ;
Pupko, T ;
Fariselli, P ;
Casadio, R ;
Ben-Tal, N .
BIOINFORMATICS, 2004, 20 (08) :1322-1324
[3]  
*CARD U, 2004, HUM FEN MUT DAR I ME
[4]  
den Dunnen JT, 2000, HUM MUTAT, V15, P7
[5]   Nomenclature for the description of human sequence variations [J].
den Dunnen, JT ;
Antonarakis, E .
HUMAN GENETICS, 2001, 109 (01) :121-124
[6]  
DENDUNNEN IT, 2007, NOMENCLATURE DESCRIP
[7]   Association of RET protooncogene codon 45 polymorphism with Hirschsprung disease [J].
Fitze, G ;
Schreiber, M ;
Kuhlisch, E ;
Schackert, HK ;
Roesner, D .
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (05) :1469-1473
[8]   AMINO-ACID DIFFERENCE FORMULA TO HELP EXPLAIN PROTEIN EVOLUTION [J].
GRANTHAM, R .
SCIENCE, 1974, 185 (4154) :862-864
[9]  
Kazazian HA, 2000, GENET MED, V2, P302
[10]  
*NCBI, NCBI REFS DAT NAT CT